Aligos Therapeutics, Inc. (ALGS)

US — Healthcare Sector
Peers: CTMX  SPRO  NLTX  TIL  NXTC  ASMB  ACHL  NUVB 

Automate Your Wheel Strategy on ALGS

With Tiblio's Option Bot, you can configure your own wheel strategy including ALGS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ALGS
  • Rev/Share 0.3889
  • Book/Share 13.8485
  • PB 0.4369
  • Debt/Equity 0.0676
  • CurrentRatio 7.5578
  • ROIC -0.6427

 

  • MktCap 36994540.0
  • FreeCF/Share -9.3965
  • PFCF -0.4682
  • PE -0.9552
  • Debt/Assets 0.0522
  • DivYield 0
  • ROE -1.0402

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 2
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation ALGS H.C. Wainwright -- Buy -- $75 Aug. 19, 2024

News

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ALGS
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral

SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 26,000 shares of the Company's stock (the “Inducement Grant”) to a newly hired employee on May 13, 2025 (the “Grant Date”), in connection with the commencement of employment.

Read More
image for news Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025
ALGS
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from eight presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands.

Read More
image for news Aligos Therapeutics Presents Positive Data at the EASL Congress 2025
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates
ALGS
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative

Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $2.11 per share versus the Zacks Consensus Estimate of a loss of $2.80. This compares to loss of $5.50 per share a year ago.

Read More
image for news Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
ALGS
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the first quarter 2025.

Read More
image for news Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
ALGS
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral

SOUTH SAN FRANCISCO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company's first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets.

Read More
image for news Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
Aligos Therapeutics Presents Positive Data at APASL 2025
ALGS
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from three oral presentations at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2025, being held March 26 - 30, 2025 in Beijing, China.

Read More
image for news Aligos Therapeutics Presents Positive Data at APASL 2025
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates
ALGS
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Negative

Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares to loss of $5.50 per share a year ago.

Read More
image for news Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates
Aligos Therapeutics Announces $105 Million Private Placement Financing
ALGS
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into the second half of 2026 SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $105 million, before deducting placement agents' fees and other expenses.

Read More
image for news Aligos Therapeutics Announces $105 Million Private Placement Financing

About Aligos Therapeutics, Inc. (ALGS)

  • IPO Date 2020-10-16
  • Website https://www.aligos.com
  • Industry Biotechnology
  • CEO Dr. Lawrence M. Blatt MBA, Ph.D.
  • Employees 70

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.